The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1517
March 27, 2017
View Complete Issue         Table of Contents 2019 
Bezlotoxumab (Zinplava) for Prevention of Recurrent Clostridium difficile Infection
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Bezlotoxumab (Zinplava) for Prevention of Recurrent Clostridium difficile Infection
March 27, 2017 (Issue: 1517)
The FDA has approved the fully human monoclonal antibody bezlotoxumab (Zinplava – Merck) for use with antibacterial drug treatment to reduce recurrence of Clostridium difficile infection (CDI) in adults with CDI at high risk for recurrence. It...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Bezlotoxumab (Zinplava) for Prevention of Recurrent Clostridium difficile Infection
Article code: 1517a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.